Study of the Cognition of Patients Treated With Immunotherapy (COG-IMMUNO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03599830|
Recruitment Status : Recruiting
First Posted : July 26, 2018
Last Update Posted : November 26, 2019
The investigator's longitudinal pilot study aims to evaluate for the first time the impact of immunotherapy on cognition in oncology.
Due to the recent nature of immunotherapy, its side effects and impact on quality of life are still poorly understood and, to date, there is no published study evaluating the impact of immunotherapy on cognition in patients treated for cancer.
The study consists of the passation of 3 neuropsychological assessments over a period of 6 months in cancer patients who start immunotherapy
|Condition or disease||Intervention/treatment||Phase|
|Patients With Cancer Who Start Immunotherapy All Neoplasms||Other: Cognitive test passations||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of the Cognition of Patients Treated With|
|Actual Study Start Date :||July 10, 2018|
|Estimated Primary Completion Date :||April 2022|
|Estimated Study Completion Date :||October 2022|
Cognitive test passations
3 neuropsychological passations over a period of 6 months.
Other: Cognitive test passations
MoCA2 Hopkins verbal learning test WAIS-IV Trail Making test Stroop Verbal fluences
- Change in cognitive function (at least in a cognitive domain) [ Time Frame: between inclusion and 3 months. ]The proportion of patients who will have a reduction of scores in neuropsychological questionnaires (scores of MoCA2, Hopkins verbal learning test, WAIS-IV, Trail Making test, Stroop Symboles)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03599830
|Contact: Florence JOLY, Profemail@example.com|
|Contact: Mathieu BOONE, MD|
|Centre François Baclesse||Recruiting|
|Contact: Florence JOLY, Prof|
|Chru Lille||Not yet recruiting|
|Contact: Laurent MORTIER, Pr|